Literature DB >> 17332880

Infectious disease, the innate immune response, and fibrosis.

Alessia Meneghin1, Cory M Hogaboam.   

Abstract

The unrelenting and destructive progression of most fibrotic responses in the pulmonary, cardiovascular, integumentary, and alimentary systems remains a major medical challenge for which therapies are desperately needed. The pathophysiology of fibrosis remains an enigma, but considerable research and debate surrounds the question of whether chronic inflammation is the key driver of unrestrained wound healing (i.e., the fibrotic response) in these and other organ systems. This Review describes how infectious pathogens, chronic inflammation, and unrestrained fibroproliferation are likely to be part of a dynamic, unrelenting process propelling human fibrotic diseases.

Entities:  

Mesh:

Year:  2007        PMID: 17332880      PMCID: PMC1804377          DOI: 10.1172/JCI30595

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  125 in total

Review 1.  Alternatively activated macrophages during parasite infections.

Authors:  Wim Noël; Geert Raes; Gholamreza Hassanzadeh Ghassabeh; Patrick De Baetselier; Alain Beschin
Journal:  Trends Parasitol       Date:  2004-03

Review 2.  Toll-like receptors: linking innate and adaptive immunity.

Authors:  Chandrashekhar Pasare; Ruslan Medzhitov
Journal:  Adv Exp Med Biol       Date:  2005       Impact factor: 2.622

Review 3.  Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation.

Authors:  R S Smith; T J Smith; T M Blieden; R P Phipps
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

Review 4.  Fibrosis as a therapeutic target post-myocardial infarction.

Authors:  Fiona See; Andrew Kompa; Jennifer Martin; Dion A Lewis; Henry Krum
Journal:  Curr Pharm Des       Date:  2005       Impact factor: 3.116

5.  Alveolar damage in AIDS-related Pneumocystis carinii pneumonia.

Authors:  T L Benfield; P Prentø; J Junge; J Vestbo; J D Lundgren
Journal:  Chest       Date:  1997-05       Impact factor: 9.410

6.  Increased antigen-specific Th-2 response in allergic bronchopulmonary aspergillosis (ABPA) in patients with cystic fibrosis.

Authors:  M Skov; L K Poulsen; C Koch
Journal:  Pediatr Pulmonol       Date:  1999-02

7.  Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent.

Authors:  P G Fallon; E J Richardson; G J McKenzie; A N McKenzie
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

8.  Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection.

Authors:  Aileen Marshall; Simon Rushbrook; Susan E Davies; Lesley S Morris; Ian S Scott; Sarah L Vowler; Nicholas Coleman; Graeme Alexander
Journal:  Gastroenterology       Date:  2005-01       Impact factor: 22.682

9.  Murine gammaherpes virus as a cofactor in the development of pulmonary fibrosis in bleomycin resistant mice.

Authors:  S S Lok; Y Haider; D Howell; J P Stewart; P S Hasleton; J J Egan
Journal:  Eur Respir J       Date:  2002-11       Impact factor: 16.671

10.  Anti-IL-4 treatment of Schistosoma mansoni-infected mice inhibits development of T cells and non-B, non-T cells expressing Th2 cytokines while decreasing egg-induced hepatic fibrosis.

Authors:  A W Cheever; M E Williams; T A Wynn; F D Finkelman; R A Seder; T M Cox; S Hieny; P Caspar; A Sher
Journal:  J Immunol       Date:  1994-07-15       Impact factor: 5.422

View more
  74 in total

Review 1.  Fibrosis: ultimate and proximate causes.

Authors:  Victor J Thannickal; Yong Zhou; Amit Gaggar; Steven R Duncan
Journal:  J Clin Invest       Date:  2014-11-03       Impact factor: 14.808

Review 2.  The extracellular matrix: an active or passive player in fibrosis?

Authors:  Thomas N Wight; Susan Potter-Perigo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-04-21       Impact factor: 4.052

3.  Engineering macrophages to control the inflammatory response and angiogenesis.

Authors:  K V Eaton; H L Yang; C M Giachelli; M Scatena
Journal:  Exp Cell Res       Date:  2015-11-21       Impact factor: 3.905

Review 4.  Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.

Authors:  Thomas A Wynn
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

5.  Overactive Epidermal Growth Factor Receptor Signaling Leads to Increased Fibrosis after Severe Acute Respiratory Syndrome Coronavirus Infection.

Authors:  Thiagarajan Venkataraman; Christopher M Coleman; Matthew B Frieman
Journal:  J Virol       Date:  2017-05-26       Impact factor: 5.103

6.  What differentiates normal lung repair and fibrosis? Inflammation, resolution of repair, and fibrosis.

Authors:  Robert M Strieter
Journal:  Proc Am Thorac Soc       Date:  2008-04-15

7.  Central nervous system fibrosis is associated with fibrocyte-like infiltrates.

Authors:  Amy Aldrich; Tammy Kielian
Journal:  Am J Pathol       Date:  2011-10-18       Impact factor: 4.307

Review 8.  Toll like receptors in diseases of the lung.

Authors:  Melissa A Kovach; Theodore J Standiford
Journal:  Int Immunopharmacol       Date:  2011-05-30       Impact factor: 4.932

Review 9.  Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.

Authors:  Tanjina Akter; Richard M Silver; Galina S Bogatkevich
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

10.  NF-kappaB blockade upregulates Bax, TSP-1, and TSP-2 expression in rat granulation tissue.

Authors:  Daniela De Stefano; Giancarlo Nicolaus; Maria Chiara Maiuri; Daniela Cipolletta; Lorenzo Galluzzi; Maria Pia Cinelli; Gianfranco Tajana; Teresa Iuvone; Rosa Carnuccio
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.